Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS) - 24/03/15
, Jean-Pierre Bronowicki, MD b, Victor de Ledinghen, MD c, Christophe Hézode, MD d, Fabien Zoulim, MD e, Philippe Mathurin, MD f, Albert Tran, MD g, Dominique G Larrey, MD h, Vlad Ratziu, MD i, Laurent Alric, MD j, Robert H Hyland, DPhil k, Deyuan Jiang, PhD k, Brian Doehle, PhD k, Phillip S Pang, MD k, William T Symonds, PharmD k, G Mani Subramanian, MD k, John G McHutchison, MD k, Patrick Marcellin, MD l, François Habersetzer, MD m, Dominique Guyader, MD n, Jean-Didier Grangé, MD o, Véronique Loustaud-Ratti, MD p, Lawrence Serfaty, MD q, Sophie Metivier, MD r, Vincent Leroy, MD s, Armand Abergel, MD t, Stanislas Pol, MD uSummary |
Background |
Patients with cirrhosis resulting from chronic hepatitis C virus (HCV) infection are at risk of life-threatening complications, but consistently achieve lower sustained virological response (SVR) than patients without cirrhosis, especially if treatment has previously failed. We assessed the efficacy and safety of the NS5A inhibitor ledipasvir and the nucleotide polymerase inhibitor sofosbuvir, with and without ribavirin.
Methods |
In this multicentre, double-blind trial, between Oct 21, 2013, and Oct 30, 2014, we enrolled patients with HCV genotype 1 and compensated cirrhosis who had not achieved SVR after successive treatments with pegylated interferon and protease-inhibitor regimens at 20 sites in France. With a computer-generated randomisation sequence, patients were assigned in a 1:1 ratio to receive placebo matched in appearance to study drugs for 12 weeks followed by once daily combination fixed-dose tablets of 90 mg ledipasvir and 400 mg sofosbuvir plus weight-based ribavirin for 12 weeks, or ledipasvir-sofosbuvir plus placebo once daily for 24 weeks. The primary endpoint was SVR 12 weeks after the end of treatment (SVR12), for which 95% CIs were calculated with the Clopper-Pearson method. This study is registered with ClinicalTrials.gov, number NCT01965535.
Findings |
Of 172 patients screened, 155 entered randomisation, 77 were assigned to receive ledipasvir-sofosbuvir plus ribavirin and 78 ledipasvir-sofosbuvir. 114 (74%) were men, 151 (97%), were white, 98 (63%) had HCV genotype 1a, and 145 (94%) had non-CC IL28B alleles. SVR12 rates were 96% (95% CI 89–99) for patients in the ledipasvir-sofosbuvir plus ribavirin group and 97% (91–100) in the ledipasvir-sofosbuvir group. One patient discontinued treatment because of adverse events while receiving only placebo. The most frequent adverse events were asthenia and headache, pruritus, and fatigue.
Interpretation |
Ledipasvir-sofosbuvir plus ribavirin for 12 weeks and ledipasvir-sofosbuvir for 24 weeks provided similarly high SVR12 rates in previous non-responders with HCV genotype 1 and compensated cirrhosis. The shorter regimen, when given with ribavirin, might, therefore, be useful to treat treatment-experienced patients with cirrhosis if longer-term treatment is not possible.
Funding |
Gilead Sciences.
Le texte complet de cet article est disponible en PDF.Plan
Vol 15 - N° 4
P. 397-404 - avril 2015 Retour au numéro
Article précédent
- Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial
- Antoine Chéret, Georges Nembot, Adeline Mélard, Caroline Lascoux, Laurence Slama, Patrick Miailhes, Patrick Yeni, Sylvie Abel, Véronique Avettand-Fenoel, Alain Venet, Marie-Laure Chaix, Jean-Michel Molina, Christine Katlama, Cécile Goujard, Catherine Tamalet, François Raffi, Alain Lafeuillade, Jacques Reynes, Isabelle Ravaux, Bruno Hoën, Jean-François Delfraissy, Laurence Meyer, Christine Rouzioux, for the OPTIPRIM ANRS Study Group †
- Comparison of two-dose priming plus 9-month booster with a standard three-dose priming schedule for a ten-valent pneumococcal conjugate vaccine in Nepalese infants: a randomised, controlled, open-label, non-inferiority trial
- Mainga Hamaluba, Rama Kandasamy, Shyam R Upreti, Giri R Subedi, Shrijana Shrestha, Shiva Bhattarai, Meeru Gurung, Rahul Pradhan, Merryn Voysey, Santosh Gurung, Shachi Pradhan, Anushil K Thapa, Rakesh Maharjan, Usha Kiran, Simon A Kerridge, Jason Hinds, Fiona van der Klis, Matthew D Snape, David R Murdoch, Sarah Kelly, Dominic F Kelly, Neelam Adhikari, Stephen Thorson, Andrew J Pollard
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?